Califf Wins Narrow Senate Vote for Second Turn as FDA Commissioner
In a 50-46 vote, the Senate confirmed Robert Califf, MD, as President Biden’s FDA commissioner. The agency has been without a permanent leader for more than a year.
UK Authority: Merck Used Illegal Discounts to Defend Against Biosimilar Competition to Remicade
Certolizumab Responsible for Higher Costs, Pneumonia Rates Than Adalimumab, Etanercept
AbbVie Loses Humira Patent Challenge to Coherus
Framework Proposed to Incorporate Biosimilars Education Into Pharmacist Curriculum
European Guide for Prescribers Assures Safety and Effectiveness of Biosimilars
JAMA Viewpoint Explores Barriers to Biosimilar Uptake for Chronic Diseases
Fresenius Kabi to Purchase Merck KGaA Biosimilars Arm for €670 Million
Rituximab Biosimilar Estimated to Save €90 Million Annually in the EU
Nebraska Legislature Debates Biosimilar Substitution Bill
Prescribers in England Turn to Biosimilar Growth Hormones for Ease of Use, Not Cost
European Drug Agency's Move Out of London, Spurred By Brexit, Could Disrupt Pipeline
New Research Compares Effectiveness, Safety of Branded and Biosimilar Filgrastim
Infographic: A Guide to Briefs in the Amgen vs Sandoz Supreme Court Case
Payer Cost Savings From Filgrastim Biosimilars Could Reach $2 Million Annually
Infographic: Biosimilar Substitution Laws By State
Dr Scott Gottlieb, Trump's FDA Pick, a Consistent Supporter of Biosimilar Innovation
Merck KGaA Close to Selling Biosimilars Division to Undisclosed Buyer
Sandoz Releases Efficacy Data for Its Humira Biosimilar
Bioequivalence Endpoints Successfully Met for Humira Biosimilar, Coherus Announces
Diabetes Drugs Could Be Next Frontier of Biosimilar Development
Truxima Receives Approval in EU for Autoimmune, Oncology Indications
Bevacizumab Biosimilar Could Address Global Barriers to Access
Biosimilar Knowledge Gaps Identified Among US Specialty Physicians
EMA Pilot Will Provide Tailored Advice to Biosimilar Developers, Similar to FDA Process
EMA Concerns Prompt Sandoz to Withdraw Neulasta Biosimilar Application
FDA Hiring Freeze Could Slow Down Biosimilar Approval Process
